Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 10, pp. 951-963
Open Access | Times Cited: 116

Showing 26-50 of 116 citing articles:

COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint
Luca M. Zaeck, Corine H. GeurtsvanKessel, Rory D. de Vries
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 395-396
Open Access | Times Cited: 12
Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity
Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1104-1117
Open Access | Times Cited: 12
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program
Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice
Muhammad S. Khan, Eun Sun Kim, Shaohua Huang, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 314-314
Open Access | Times Cited: 11
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
Xiaoyin Zhang, Jiayue Xia, Lairun Jin, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 11
Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis
Saeed Taheri
International Urology and Nephrology (2023) Vol. 55, Iss. 4, pp. 791-802
Open Access | Times Cited: 10
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
Eun Kim, Muhammad S. Khan, Alessandro Ferrari, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 10
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Catherine Riou, Jinal N. Bhiman, Yashica Ganga, et al.
PLOS Global Public Health (2024) Vol. 4, Iss. 4, pp. e0002703-e0002703
Open Access | Times Cited: 3
Safety, immunogenicity, and protective effective of inhaled COVID‐19 vaccines: A systematic review and meta‐analysis
Song Gao, Rong Li, Meng-Qun Cheng
Journal of Medical Virology (2024) Vol. 96, Iss. 4
Open Access | Times Cited: 3
COVID-19 Vaccines in Older Adults
Chih‐Kuang Liang, Wei‐Ju Lee, Li‐Ning Peng, et al.
Clinics in Geriatric Medicine (2022) Vol. 38, Iss. 3, pp. 605-620
Open Access | Times Cited: 16
Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial
Chih-Hsien Chuang, Chung‐Guei Huang, Ching‐Tai Huang, et al.
Journal of Clinical Virology (2022) Vol. 157, pp. 105328-105328
Open Access | Times Cited: 16
Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period—United States, 1 January 2022 to 31 March 2022
Lyudmyla Kompaniyets, Ryan E. Wiegand, Adewole C Oyalowo, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1753-1760
Open Access | Times Cited: 9
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Alice Cho, Frauke Muecksch, Zijun Wang, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 8
Open Access | Times Cited: 15
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Yana Debie, Jonas R.M. Van Audenaerde, Timon Vandamme, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 635-646
Open Access | Times Cited: 14
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Holly A. Fryer, Gemma E. Hartley, Emily S.J. Edwards, et al.
Biochemical Society Transactions (2022) Vol. 50, Iss. 6, pp. 1643-1658
Open Access | Times Cited: 14
Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 14
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
Hakjun Hyun, A-Yeung Jang, Heedo Park, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Assessment of the impact of a personalised nutrition intervention in impaired glucose regulation over 26 weeks: a randomised controlled trial
Maria Karvela, Caroline T. Golden, Nikeysha Bell, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy
Rita C. Acúrcio, Ron Kleiner, Daniella Vaskovich‐Koubi, et al.
Advanced Science (2024) Vol. 11, Iss. 40
Open Access | Times Cited: 2
COVID-19 Vaccines—All You Want to Know
Akira Shishido, Ashley H. Barnes, Shivakumar Narayanan, et al.
Seminars in Respiratory and Critical Care Medicine (2023) Vol. 44, Iss. 01, pp. 143-172
Closed Access | Times Cited: 7
Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies
Mark M. Painter, Timothy S. Johnston, Kendall A. Lundgreen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
Stefania Capone, Francesco Maria Fusco, Stefano Milleri, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 6, pp. 101084-101084
Open Access | Times Cited: 7
Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
Roos S. G. Sablerolles, Wim J. R. Rietdijk, Abraham Goorhuis, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e533-e536
Open Access | Times Cited: 11
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Mona Vestergaard Laursen, et al.
BMJ (2022), pp. e070483-e070483
Open Access | Times Cited: 11

Scroll to top